- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > antibacterial resistance (ABR)
- Mots-clés > antibiotic policy
- Mots-clés > antibiotic resistance
- Mots-clés > antimicrobial resistance (AMR)
- Mots-clés > Drug-resistant tuberculosis (DR-TB)
- Mots-clés > pharmaceutical industry - incentive for R&D
- Mots-clés > pharmaceutical research - priorities
- Mots-clés > prioritization of pathogens for research and development
- Mots-clés > priority diseases
- Mots-clés > priority medicines
(2017; 7 pages)
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention (CDC, Antibiotic Resistance Threats in the United States, 2013; http://www.cdc.gov/drugresistance/threat-report-2013/) and the Public Health Agency of Canada (PLoS One. 2015;10(4):1-11), focused on national public health priorities to increase scientific, political and public awareness without including specific R&D criteria.
The major objective of the global PPL is to guide the prioritization of incentives and funding, help align R&D priorities with public health needs and support global coordination in the fight against antibiotic-resistant bacteria. The WHO PPL targets policy initiatives to incentivize basic science and advanced R&D by both public funding agencies and the private sector investing in new antibiotics.